TB vaccine study in older adults aged 55 to 74
Part of Infections, Lungs & breathing clinical trials.
This study tests a new tuberculosis (TB) vaccine (ID93+GLA-SE) in healthy adults aged 55 to 74. It aims to see if the vaccine is safe and can help protect against TB, especially in people who may have latent (inactive) TB infection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 55 and 74 years old.
- You have had a BCG vaccine (TB vaccine) or have a BCG scar.
- You are generally healthy or have well-managed chronic conditions (like high blood pressure or diabetes).
- You are willing to use contraception if you are of childbearing age or have a partner who is.
- You haven't had TB, latent TB treatment, or a TB vaccine before.
- You are not pregnant, breastfeeding, or have serious health issues like active infections, cancer, or heart disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether an experimental vaccine (ID93 + GLA-SE) can improve outcomes in people being treated for drug-sensitive tuberculosis. It is for those newly diagnosed or who have been on standard TB treatment for a few months.
This trial studies whether atorvastatin (a cholesterol medicine) can reduce ongoing inflammation after you finish standard tuberculosis (TB) treatment. If it works, it may improve how your body recovers after TB, especially by lowering inflammation-related signals.
This trial tests whether a new vaccine called MTBVAC can prevent tuberculosis (TB) in people living in areas where TB is common. If you are between 14 and 45 years old and in good health, you may be able to join.
This Phase 2 study tests MTBVAC, a TB vaccine candidate, to see if it is safe and whether it helps the immune system. It may be a fit if you’re eligible for TB and HIV-related vaccine safety testing and can follow study visits and testing.
This trial tests a new vaccine designed to help protect older adults from infections that can affect breathing. You might be able to join if you're in generally good health and meet the other requirements listed below.
This study tests a new tuberculosis vaccine called Lipovaxin in healthy adults aged 18–40. Researchers want to see if it is safe and how the body responds to it, which could help prevent TB infection in the future.
Hear when a new Tuberculosis, Pulmonary trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.